Table 2.
Susceptibility of the infectious agents found in 268 samples of ascitic fluid to different antimicrobials during the period 2010-2011
| Total (n = 268) | After exclusion of coagulase negative staphylococci (n = 195) | Non-nosocomial episodes (n = 109) | Nosocomial episodes (n = 159) | P 1 | SBP (n = 57) | Bacterascites (n = 140) | P 2 | |
|---|---|---|---|---|---|---|---|---|
| Amoxicillin |
33.2% |
45.6% |
40.4% |
28.3% |
0.04 |
40.4% |
33.3% |
0.37 |
| Amoxicillin + clavulanate |
42.5% |
53.3% |
50.5% |
38.1% |
0.02 |
43.9% |
44.3% |
0.96 |
| Broad-spectrum penicillin |
35.4% |
48.7% |
38.5% |
33.3% |
0.38 |
40.4% |
39.3% |
0.89 |
| Broad-spectrum penicillin + beta lactamase inhibitor |
48.1% |
64.1% |
51.4% |
45.9% |
0.38 |
47.4% |
50.7% |
0.67 |
| Third-generation cephalosporin |
39.2% |
39.0% |
55.0% |
28.3% |
<0.0001 |
33.3% |
42.1% |
0.25 |
| Fluoroquinolone |
46.6% |
46.7% |
57.8% |
39.0% |
0.002 |
38.6% |
47.1% |
0.27 |
| Aminoglycoside |
50.0% |
47.2% |
56.9% |
45.3% |
0.06 |
47.4% |
52.9% |
0.48 |
| Cotrimoxazole |
42.2% |
38.4% |
53.2% |
34.6% |
0.002 |
29.8% |
45.7% |
0.04 |
| Glycopeptide | 57.8% | 45.6% | 60.6% | 56.0% | 0.45 | 50.9% | 66.5% | 0.04 |
Percentages indicate the in vitro antimicrobial efficacy on the infectious agent (s) isolated in positive ascitic fluid cultures.
(intermediate strains were considered non-susceptible).
1comparison between non-nosocomial and nosocomial episodes.
2comparison between SBP and bacterascites.